Bio-Rad Laboratories, Inc. (BIO) EV/Sales Ratio: 3.35x
Is Bio-Rad Laboratories, Inc.’s EV/Sales ratio high or low?
Bio-Rad Laboratories, Inc.'s EV/Sales ratio of 3.35x is 27% below its 5-year average of 4.57x, near the low end of its 5-year range (2.72x–8.47x).
As of Tuesday, June 16, 2026. 1.94% below its 12-month average of 3.42x.
BIO EV/Sales Ratio Chart
BIO Average EV/Sales Ratio Chart
BIO Current vs Average EV/Sales Ratio Chart
BIO EV/Sales Ratio Metrics
EV/SALES RATIO
3.35x
EV/SALES RATIO AVG TTM
3.42x
EV/SALES RATIO AVG 3Y
3.67x
EV/SALES RATIO AVG 5Y
4.51x
EV/SALES RATIO AVG 10Y
4.43x
EV/SALES RATIO AVG 15Y
3.53x
EV/SALES RATIO AVG 20Y
2.98x
CURRENT VS TTM AVG
-1.94%
CURRENT VS 3Y AVG
-8.73%
CURRENT VS 5Y AVG
-25.70%
CURRENT VS 10Y AVG
-24.30%
CURRENT VS 15Y AVG
-5.00%
CURRENT VS 20Y AVG
+12.39%
BIO Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 3.35x | 3.42x | 3.67x | 4.51x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.03B | 3.29x | 4.67x | 4.20x | 4.26x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.99B | 3.00x | 2.80x | 3.02x | 3.79x |
| Tempus AI, Inc. (TEM)vs › | $9.13B | 7.45x | 11.42x | 12.18x | 12.18x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.25x | 0.26x | 0.37x | 0.45x |
| Baxter International Inc. (BAX)vs › | $10.75B | 1.62x | 1.71x | 2.17x | 2.64x |
| Align Technology, Inc. (ALGN)vs › | $12.92B | 2.89x | 2.72x | 4.06x | 5.89x |
| The Cooper Companies, Inc. (COO)vs › | $13.22B | 3.67x | 4.15x | 5.16x | 5.80x |
| Solventum Corporation (SOLV)vs › | $13.32B | 2.18x | 2.19x | 2.26x | 2.26x |
| DaVita Inc. (DVA)vs › | $13.47B | 1.95x | 1.81x | 1.84x | 1.85x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Bio-Rad Laboratories, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The EV/Sales ratio for BIO stock is 3.35x.
- Is Bio-Rad Laboratories, Inc.'s EV/Sales ratio high or low?
- Bio-Rad Laboratories, Inc.'s EV/Sales ratio of 3.35x is 27% below its 5-year average of 4.57x, near the low end of its 5-year range (2.72x–8.47x).
- What is the TTM average EV/Sales ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average EV/Sales ratio for BIO stock is 3.42x.
- What is the 3Y average EV/Sales ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average EV/Sales ratio for BIO stock is 3.67x.
- What is the 5Y average EV/Sales ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average EV/Sales ratio for BIO stock is 4.51x.
- What is the 10Y average EV/Sales ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average EV/Sales ratio for BIO stock is 4.43x.
- What is the 15Y average EV/Sales ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average EV/Sales ratio for BIO stock is 3.53x.
- What is the 20Y average EV/Sales ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average EV/Sales ratio for BIO stock is 2.98x.
Bio-Rad Laboratories, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-15 | 3.35x |
| 2026-06-12 | 3.31x |
| 2026-06-11 | 3.38x |
| 2026-06-10 | 3.37x |
| 2026-06-09 | 3.43x |
| 2026-06-08 | 3.37x |
| 2026-06-05 | 3.40x |
| 2026-06-04 | 3.54x |
| 2026-06-03 | 3.51x |
| 2026-06-02 | 3.52x |
| 2026-06-01 | 3.52x |
| 2026-05-29 | 3.59x |
| 2026-05-28 | 3.65x |
| 2026-05-27 | 3.51x |
| 2026-05-26 | 3.43x |
| 2026-05-22 | 3.33x |
| 2026-05-21 | 3.32x |
| 2026-05-20 | 3.33x |
| 2026-05-19 | 3.26x |
| 2026-05-18 | 3.27x |
| 2026-05-15 | 2.91x |
| 2026-05-14 | 2.90x |
| 2026-05-13 | 2.87x |
| 2026-05-12 | 2.85x |
| 2026-05-11 | 2.87x |
| 2026-05-08 | 2.98x |
| 2026-05-07 | 3.01x |
| 2026-05-06 | 3.03x |
| 2026-05-05 | 3.01x |
| 2026-05-04 | 3.02x |
| 2026-05-01 | 3.01x |
| 2026-04-30 | 3.25x |
| 2026-04-29 | 3.26x |
| 2026-04-28 | 3.31x |
| 2026-04-27 | 3.39x |
| 2026-04-24 | 3.40x |
| 2026-04-23 | 3.33x |
| 2026-04-22 | 3.53x |
| 2026-04-21 | 3.58x |
| 2026-04-20 | 3.56x |
| 2026-04-17 | 3.51x |
| 2026-04-16 | 3.43x |
| 2026-04-15 | 3.48x |
| 2026-04-14 | 3.44x |
| 2026-04-13 | 3.40x |
| 2026-04-10 | 3.31x |
| 2026-04-09 | 3.29x |
| 2026-04-08 | 3.33x |
| 2026-04-07 | 3.29x |
| 2026-04-06 | 3.30x |
| 2026-04-02 | 3.31x |
| 2026-04-01 | 3.30x |
| 2026-03-31 | 3.30x |
| 2026-03-30 | 3.21x |
| 2026-03-27 | 3.16x |
| 2026-03-26 | 3.28x |
| 2026-03-25 | 3.25x |
| 2026-03-24 | 3.23x |
| 2026-03-23 | 3.16x |
| 2026-03-20 | 3.15x |
| 2026-03-19 | 3.16x |
| 2026-03-18 | 3.19x |
| 2026-03-17 | 3.20x |
| 2026-03-16 | 3.12x |
| 2026-03-13 | 3.13x |
| 2026-03-12 | 3.12x |
| 2026-03-11 | 3.21x |
| 2026-03-10 | 3.19x |
| 2026-03-09 | 3.23x |
| 2026-03-06 | 3.21x |
| 2026-03-05 | 3.30x |
| 2026-03-04 | 3.36x |
| 2026-03-03 | 3.32x |
| 2026-03-02 | 3.31x |
| 2026-02-27 | 3.30x |
| 2026-02-26 | 3.26x |
| 2026-02-25 | 3.21x |
| 2026-02-24 | 3.20x |
| 2026-02-23 | 3.19x |
| 2026-02-20 | 3.22x |
| 2026-02-19 | 3.23x |
| 2026-02-18 | 3.22x |
| 2026-02-17 | 3.16x |
| 2026-02-13 | 3.07x |
| 2026-02-12 | 3.44x |
| 2026-02-11 | 3.48x |
| 2026-02-10 | 3.55x |
| 2026-02-09 | 3.49x |
| 2026-02-06 | 3.56x |
| 2026-02-05 | 3.54x |
| 2026-02-04 | 3.61x |
| 2026-02-03 | 3.54x |
| 2026-02-02 | 3.52x |
| 2026-01-30 | 3.48x |
| 2026-01-29 | 3.49x |
| 2026-01-28 | 3.55x |
| 2026-01-27 | 3.52x |
| 2026-01-26 | 3.54x |
| 2026-01-23 | 3.51x |
| 2026-01-22 | 3.60x |
| 2026-01-21 | 3.67x |
| 2026-01-20 | 3.68x |
| 2026-01-16 | 3.69x |
| 2026-01-15 | 3.78x |
| 2026-01-14 | 3.74x |
| 2026-01-13 | 3.78x |
| 2026-01-12 | 3.79x |
| 2026-01-09 | 3.80x |
| 2026-01-08 | 3.75x |
| 2026-01-07 | 3.80x |
| 2026-01-06 | 3.82x |
| 2026-01-05 | 3.78x |
| 2026-01-02 | 3.60x |
| 2025-12-31 | 3.58x |
| 2025-12-30 | 3.60x |
| 2025-12-29 | 3.59x |
| 2025-12-26 | 3.59x |
| 2025-12-24 | 3.57x |
| 2025-12-23 | 3.56x |
| 2025-12-22 | 3.60x |
| 2025-12-19 | 3.56x |
| 2025-12-18 | 3.55x |
| 2025-12-17 | 3.56x |
| 2025-12-16 | 3.57x |
| 2025-12-15 | 3.63x |
| 2025-12-12 | 3.63x |
| 2025-12-11 | 3.70x |
| 2025-12-10 | 3.71x |
| 2025-12-09 | 3.63x |
| 2025-12-08 | 3.64x |
| 2025-12-05 | 3.73x |
| 2025-12-04 | 3.76x |
| 2025-12-03 | 3.76x |
| 2025-12-02 | 3.74x |
| 2025-12-01 | 3.77x |
| 2025-11-28 | 3.81x |
| 2025-11-26 | 3.83x |
| 2025-11-25 | 3.89x |
| 2025-11-24 | 3.78x |
| 2025-11-21 | 3.72x |
| 2025-11-20 | 3.59x |
| 2025-11-19 | 3.60x |
| 2025-11-18 | 3.63x |
| 2025-11-17 | 3.59x |
| 2025-11-14 | 3.69x |
| 2025-11-13 | 3.73x |
| 2025-11-12 | 3.84x |
| 2025-11-11 | 3.69x |
| 2025-11-10 | 3.63x |
| 2025-11-07 | 3.61x |
| 2025-11-06 | 3.62x |
| 2025-11-05 | 3.65x |
| 2025-11-04 | 3.66x |
| 2025-11-03 | 3.67x |
| 2025-10-31 | 3.75x |
| 2025-10-30 | 3.60x |
| 2025-10-29 | 3.75x |
| 2025-10-28 | 3.93x |
| 2025-10-27 | 3.99x |
| 2025-10-24 | 4.03x |
| 2025-10-23 | 4.02x |
| 2025-10-22 | 3.97x |
| 2025-10-21 | 3.94x |
| 2025-10-20 | 3.84x |
| 2025-10-17 | 3.71x |
| 2025-10-16 | 3.74x |
| 2025-10-15 | 3.67x |
| 2025-10-14 | 3.66x |
| 2025-10-13 | 3.64x |
| 2025-10-10 | 3.58x |
| 2025-10-09 | 3.61x |
| 2025-10-08 | 3.63x |
| 2025-10-07 | 3.57x |
| 2025-10-06 | 3.70x |
| 2025-10-03 | 3.66x |
| 2025-10-02 | 3.54x |
| 2025-10-01 | 3.58x |
| 2025-09-30 | 3.40x |
| 2025-09-29 | 3.29x |
| 2025-09-26 | 3.30x |
| 2025-09-25 | 3.29x |
| 2025-09-24 | 3.35x |
| 2025-09-23 | 3.41x |
| 2025-09-22 | 3.43x |
| 2025-09-19 | 3.43x |
| 2025-09-18 | 3.46x |
| 2025-09-17 | 3.39x |
| 2025-09-16 | 3.41x |
| 2025-09-15 | 3.39x |
| 2025-09-12 | 3.39x |
| 2025-09-11 | 3.45x |
| 2025-09-10 | 3.36x |
| 2025-09-09 | 3.45x |
| 2025-09-08 | 3.50x |
| 2025-09-05 | 3.56x |
| 2025-09-04 | 3.49x |
| 2025-09-03 | 3.48x |
| 2025-09-02 | 3.51x |
| 2025-08-29 | 3.58x |
| 2025-08-28 | 3.54x |
| 2025-08-27 | 3.53x |
| 2025-08-26 | 3.57x |
| 2025-08-25 | 3.58x |
| 2025-08-22 | 3.64x |
| 2025-08-21 | 3.44x |
| 2025-08-20 | 3.48x |
| 2025-08-19 | 3.48x |
| 2025-08-18 | 3.44x |
| 2025-08-15 | 3.45x |
| 2025-08-14 | 3.47x |
| 2025-08-13 | 3.47x |
| 2025-08-12 | 3.34x |
| 2025-08-11 | 3.23x |
| 2025-08-08 | 3.22x |
| 2025-08-07 | 3.23x |
| 2025-08-06 | 3.22x |
| 2025-08-05 | 3.31x |
| 2025-08-04 | 3.36x |
| 2025-08-01 | 3.44x |
| 2025-07-31 | 2.99x |
| 2025-07-30 | 3.08x |
| 2025-07-29 | 3.11x |
| 2025-07-28 | 3.12x |
| 2025-07-25 | 3.24x |
| 2025-07-24 | 3.22x |
| 2025-07-23 | 3.16x |
| 2025-07-22 | 3.03x |
| 2025-07-21 | 3.02x |
| 2025-07-18 | 3.04x |
| 2025-07-17 | 3.08x |
| 2025-07-16 | 3.05x |
| 2025-07-15 | 3.05x |
| 2025-07-14 | 3.09x |
| 2025-07-11 | 3.16x |
| 2025-07-10 | 3.19x |
| 2025-07-09 | 3.12x |
| 2025-07-08 | 3.09x |
| 2025-07-07 | 3.05x |
| 2025-07-03 | 3.10x |
| 2025-07-02 | 3.09x |
| 2025-07-01 | 3.06x |
| 2025-06-30 | 2.99x |
| 2025-06-27 | 3.02x |
| 2025-06-26 | 3.01x |
| 2025-06-25 | 2.98x |
| 2025-06-24 | 2.95x |
| 2025-06-23 | 2.92x |
| 2025-06-20 | 2.94x |
| 2025-06-18 | 2.89x |
| 2025-06-17 | 2.87x |
| 2025-06-16 | 2.88x |
| 2025-06-13 | 2.83x |
| 2025-06-12 | 2.89x |
| 2025-06-11 | 2.87x |
| 2025-06-10 | 2.87x |
| 2025-06-09 | 2.82x |
| 2025-06-06 | 2.75x |
| 2025-06-05 | 2.75x |
| 2025-06-04 | 2.78x |
| 2025-06-03 | 2.76x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz